TYK2 inhibitor class reference (2026)
Reference snapshot of approved TYK2 inhibitors, their indications, and the positioning relative to JAK class agents.
Approved TYK2 inhibitors in 2026 cover psoriasis (deucravacitinib) with active expansion programs across psoriatic arthritis, ulcerative colitis, lupus, and additional immunology indications. The class differentiates from JAK inhibitors on selectivity (TYK2 has a narrower kinase profile) and the resulting tolerability profile.
Positioning has settled. TYK2 inhibitors compete in the post-biologic tier in psoriasis with a tolerability advantage emphasised relative to JAK class. In future indications (PsA, UC, lupus) the same positioning is likely. The follow-on TYK2 inhibitors entering pivotal trials will need to differentiate on indication breadth or tolerability headroom rather than adding to the existing tier.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.